Lenalidomide maintenance for brain and eye lymphoma
Part of Brain & nervous system, Cancer, Eyes & vision clinical trials.
This trial tests whether taking lenalidomide after initial treatment helps keep primary central nervous system lymphoma or primary vitreoretinal lymphoma from coming back. It is for patients who have finished standard chemotherapy and radiation and are in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with a certain type of lymphoma in the brain or eye.
- You have completed standard chemotherapy and radiation and your disease is in remission (complete or partial response).
- You are able to have MRI scans and spinal taps (or a special port for medication).
- Your major organs (heart, lungs, liver, kidneys) and bone marrow are working well enough.
- You are able to take oral medication and are willing to use effective contraception if needed.
- You have not had lenalidomide or whole-brain radiation before, and you are not planning a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies lenalidomide taken after your first treatment has worked for primary central nervous system lymphoma (PCNSL). It aims to help keep the lymphoma from coming back by testing lenalidomide as ongoing “maintenance” treatment.
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
This trial tests whether a maintenance drug called obinutuzumab can help prevent relapse in people with primary central nervous system lymphoma (a rare lymphoma in the brain or spine) who have already responded to initial chemotherapy. It is for those who have achieved at least a partial or complete response to their first treatment.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
Hear when a new Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.